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Chronic mucocutaneous candidiasis (CMC) is a heterogeneous 
group of disorders characterised by a selective inability to 
clear candida organisms and occasionally dermatophytic 
fungi, especially Trichophyton and Microsporum. This results 
in debilitating, refractory and persistent mucocutaneous 
infections affecting the skin, mucous membranes and nails. 
The cutaneous lesions often present as thick crusts on the 
scalp and face and some patients may have cutaneous horn 
formation. On biopsy these skin lesions show infiltration by 
lymphocytes, plasma cells and giant cells and for this reason 
have been called candida granulomas (Fig. 1).1 Patients rarely 
develop sepsis or life-threatening candida infection, suggesting 
that there is not a generalised immune deficiency but rather 
a defect in the specific anti-candida T-cell response. A variety 
of these defects have now been described, some of which are 
associated with endocrinopathies or autoimmune diseases such 




This rare disease goes by a variety of other names 
including autoimmune polyglandular syndrome (APS), 
polyglandular autoimmune syndrome (PGA) and autoimmune 
polyendocrinopathy syndrome. Although APECED is generally 
rare, it is more frequent in certain populations: the Finnish, 
Iranian Jews, and Sardinians. It appears early in life, typically 
in infants presenting with persistent candidal infection 
(Fig. 2). This form of candidiasis is associated with a variety 
of autoimmune disorders including hypoparathyroidism, 
alopecia areata, vitiligo, adrenal insufficiency and pernicious 
anaemia. Autoimmune disorders may continue to appear 
throughout the life of these patients and type 1 diabetes will 
appear in about 18% of them.2 Typically, the patients display 
a variety of autoantibodies against intracellular key enzymes 
present in the affected organs.3 The disease, which is a rare 
autosomal recessive disorder, is caused by mutations in the 
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Fig. 1. A patient diagnosed by Professor Koornhof with a severe 
granulomatous form of chronic mucocutaneous candidiasis. The large 
lesion on the side of the face contained large numbers of Candida albicans 
and a very marked granulomatous reaction.
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autoimmune regulator gene (AIRE) that has been mapped to 
chromosome region 21q22.3. The gene encodes a protein with 
the characteristics of a transcription factor and is expressed in 
various tissues, including the thymus and the lymph nodes. 
AIRE normally plays a role in the thymus in regulating 
expression of a subset of autoantigens derived from peripheral 
tissues. Normally, potentially autoaggressive T-cells that 
recognise these antigens are deleted, but they are presumed 
to escape to the periphery in patients with AIRE mutations 
leading to autoimmune attack on selected organs. AIRE is 
also expressed in peripheral dendritic cells and is thought to 
be involved in the maintenance of peripheral immunological 
tolerance.4 Recently,5 it has been shown that AIRE-deficient 
patients show reduced regulatory T-cell (TREG) activity. The 
CD4+CD25+ cells show decreased function in these patients 
and this could account for their lack of self-tolerance and the 
development of autoimmune disease. How mutations of this 
gene lead to susceptibility to candida organisms is unclear, 
but the infection is difficult to treat and has resulted in oral 
or oesophageal squamous carcinoma in 10% of patients.6 Of 
particular interest is the observation that most of these patients 
have high-titre IgG auto-antibodies against interferon-alpha 
and especially against its subtype interferon-omega.7 Many 
of the patients also have antibodies to interferon-beta. These 
antibodies are neutralising in nature and may offer some clues 
to the susceptibility to candida and other fungal organisms.7
Chronic mucocutaneous candidiasis is 
associated with various immunological 
defects
Protection against systemic disseminated candida infection 
relies on antibodies interacting with neutrophils, hence 
the observation that invasion is usually seen in patients on 
immunosuppressive or cytotoxic therapy. Protection against 
mucocutaneous candidiasis, however, depends on cell-
mediated immunity, hence its occurrence in patients with AIDS 
or severe combined immunodeficiency. It is not surprising 
therefore that numerous reports have documented abnormal 
T-lymphocyte function in patients with CMC and a variety 
of defects have been described mainly related to deficient 
cytokine production. In a detailed study of 24 CMC patients 
Lilic et al.8 showed that some CMC patients have abnormal 
cytokine production specifically against candida antigen, 
whereas others fail to produce certain cytokines when their 
lymphocytes are activated even by non-candida antigens. Most 
of the patients have impaired cytokine production by the TH1 
cell population and this includes IL-12, IL-2 and IFNγ. This 
impairment was more general in nature although it was most 
pronounced in response to candida antigens. In a study of 7 
CMC patients, Van der Graaf et al.9 demonstrated decreased 
IFNγ production when whole blood was stimulated with C. 
albicans antigens. This was associated with an increase in the 
IL-10 production.
IL-12 is a key cytokine in the activation of TH1 cells and 
the subsequent production of IFNγ, an important activator of 
macrophages and dendritic cells. The IL-12 and IFNγ signalling 
pathways are therefore crucial for the intracellular microbicidal 
function of cell-mediated immunity. In a mouse candida 
model IFNγ was shown to be important for development of 
IL-12-dependent protective TH1 responses to candida.10 In 
those studies mice deficient in IFNγ receptors failed to mount 
protective TH1-mediated immunity to candida. A group of 
patients with inborn deficiencies of the receptors for IFNγ 
and IL-12 have been shown to be susceptible to infection 
with atypical mycobacteria but some also had persistent 
candidiasis.10  Most patients with CMC, however, show 
normal cytokine receptor expression for both IFNγ and IL-12 
receptors.11 This eliminates the possibility that the defect in 
CMC might be due to impaired binding of cytokine. 
Concomitant with the decreased production of TH1-type 
cytokines, Lilic and Gravenor12  have demonstrated increased 
production of inflammatory cytokines including tumour 
necrosis factor (TNFα) and IL-6 as well as significant increases 
in IL-10. They suggest that these high IL-10 levels could lead to 
down-regulation of the TH1 cells which would explain the low 
levels of IL-12 and IFNγ in these patients. 
It is unclear whether the defect in CMC is at the level of 
the T-cell or the antigen-presenting cell. It is unlikely that the 
TH1 defect is due to increased production of TH2 cytokines 
as it has been shown that there is no overproduction of IL-4 
and IL-10 in CMC.13 T-cells in these patients usually respond 
to nonspecific mitogens and other non-candida antigens 
suggesting that the defect probably involves the accessory 
cells. It is possible therefore that macrophages or dendritic 
cells may have defective candida antigen-presenting ability 
Fig. 2. Candida infection of the nails in a child with the APECED 
syndrome.
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or may have defective cytokine production. Romani et al.14 
have shown that dendritic cells using mannose receptors to 
phagocytose candida, activate type-1 cytokine responses from 
T-cells. However, if the organisms gained entrance through 
the dendritic cell’s Fcγ receptor this led to the onset of type-2 
responses with associated pathology in experimental animals. 
It is possible therefore that the organism and the dendritic cell 
share the responsibility for pathogenicity of C. albicans.
Familial chronic nail candidiasis 
associated with ICAM-1 deficiency
Zuccarello et al.15 described a rare and unique Sicilian family 
with candidiasis affecting only the nails of the hands and 
the feet. This family included 11 affected subjects in five 
generations, all of whom had low serum levels of intercellular 
adhesion molecule-1 (ICAM-1). This is a glycoprotein adhesion 
molecule which plays a central role in cell-to-cell interactions 
especially in T-cell activation and in leucocyte recruitment. 
Of particular interest in this family was the restriction of the 
disease to nails only, and the neonatal onset of the disorder.
Chronic mucocutaneous candidiasis 
and thyroid disease
Patients with CMC have a high incidence of endocrinopathies 
usually associated with APECED (see above).  Such patients 
typically develop hypoparathyroidism and adrenal failure and 
thyroid disease is not a major feature. Atkinson et al.16 have 
described a large family with an autosomal dominant form 
of CMC associated with hypothyroidism and with a gene 
defect localised to chromosome 2p. Interestingly in this family 
the most consistent immunological feature was a depressed 
serum IgM concentration, although there were also significant 
aberrant T-cell responses. 
Chronic mucocutaneous candidiasis 
with selective antibody deficiency
Most patients with CMC have a selective defect of cell-
mediated immunity. Kalfa et al.,17 however, have identified 9 
CMC patients with selective antibody deficiencies and bacterial 
infections. IgG2 deficiency was present in all these patients and 
was associated with IgG4 and IgA deficiency in a number of 
them. 
Conclusions
A significant subgroup of CMC patients will develop a variety 
of autoimmune endocrinopathies as part of APECED due 
to a mutation of the AIRE gene. The reason for the chronic 
candidiasis and its relationship to the endocrinopathies in these 
patients is unclear.
Most CMC patients show abnormal T-cell function, 
especially deficient production of TH1-type cytokines including 
IFNγ, which is an important macrophage and dendritic 
cell-activating factor. It is unclear if the defect is primarily 
a T-cell aberration or if it is due to an antigen-presenting 
cell abnormality. It is becoming clear that innate immune 
mechanisms play a significant role in protection against 
candidiasis and there appears to be an essential requirement 
for the IL-1R-dependent pathway.18 It is possible that abnormal 
innate immune reactions to a candida infection might result 
in aberrant activation of T-regulatory cells negatively affecting 
TH1 cell function. These areas of cell-mediated immunity 
need to be explored in patients with CMC before significant 
therapeutic progress will be made in this disease.
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